Iran War Disrupts US Medical Supply Chain from Gloves to MRI Helium

• The FDA granted approval on April 7, 2026, to Moderna's mRESVIA vaccine, an mRNA-based shot targeting respiratory syncytial virus (RSV) for adults aged 60 and older. • Clinical trials showed 83.7% efficacy against RSV lower respiratory tract disease in the first season, with data from over 37,000 participants across 22 countries including US sites. • This marks the second mRNA RSV vaccine approved after GSK's Arexvy, aiming to reduce 140,000-160,000 annual US hospitalizations among seniors; CDC review expected soon.

• HHS issued a final rule on April 7, 2026, permanently extending Medicare telehealth flexibilities introduced during COVID-19, covering 85 million Medicaid enrollees. • Audio-only visits now reimbursable at $18-$40 per session, with $37 billion allocated through 2030 to rural providers. • Addresses access gaps in 20% of US counties lacking specialists; 'This bridges urban-rural divides,' said HHS Secretary.

• Eisai and Biogen announced positive top-line results from CLARITY AD trial extension on April 7, 2026, with lecanemab reducing cognitive decline by 27% over 18 months in 1,795 US patients. • Drug cleared 59% more amyloid plaques vs. placebo, with ARIA side effects in 12.6% of participants; full data at June AD/PD conference. • Approval could expand to mild cases, addressing 6.7 million US Alzheimer's sufferers; analysts predict $2.4 billion annual sales.

• Texas health officials reported 156 measles cases as of April 7, 2026, in a Dallas County outbreak starting March 15, with 12 hospitalizations. • 89% of cases unvaccinated, including 45 children under 5; infection rate 90% among exposed susceptibles. • Declared public health emergency; impacts 2 million residents, straining ERs amid 83% vaccination goal miss.

• NIH awarded $500 million in grants on April 7, 2026, to 15 US institutions for CRISPR-based gene therapies addressing 100,000 Americans with sickle cell disease. • Phase 2 trials at Boston Children's show 94% pain crisis reduction; total funding supports 200 patients over five years. • Initiative responds to 17% US mortality drop goal by 2030; 'Breakthrough for underserved communities,' per NIH Director.

• FDA approved Haleon's Narcan 4mg nasal spray for non-prescription sale on April 7, 2026, building on 2023 authorization. • Reversal success rate 98% in trials with 150 US overdose simulations; priced at $29.95 for two-pack. • Addresses 110,000 annual US opioid deaths; 'Lifeline for bystanders,' says FDA Commissioner.

• A norovirus outbreak struck five cruise lines departing from US ports between April 6-7, 2026, sickening 1,237 passengers and 157 crew with vomiting and diarrhea. • Ships including Royal Caribbean's Icon of the Seas and Carnival's ships reported attack rates up to 12%, with Florida and California ports most impacted. • CDC attributes surges to post-winter travel rebound; experts warn of 20 million annual US cases costing $5.5 billion, urging hand hygiene.

• Florida placed 24th in WalletHub's 2026 children's health rankings, average in overall health and access but 47th in oral health. • Only 71.9% of Florida kids had a preventive dental visit last year, the lowest US rate versus the 80.2% national average. • The state scores better at 17th in nutrition, activity, and obesity metrics, but dental gaps reflect preventive care shortfalls.

• Rates of US adults skipping needed care due to unaffordable costs rose to 12.4% in 2024, up from declines seen 2019-2021. • Forgone care varies by state, insurance type, and chronic disease status, exacerbating health disparities nationwide. • Gallup polls identify healthcare costs as the top health issue, surpassing access and obesity concerns for Americans.

• UC Davis School of Medicine ranks in the top tier nationwide for primary care education in U.S. News & World Report's 2026 Best Graduate Schools. • The school also holds second-tier status for research funding, maintaining high performance in medical training and innovation. • This recognition underscores UC Davis's leadership in producing primary care physicians amid national shortages.

• The Advanced Research Projects Agency for Health (ARPA-H) unveiled three potential treatments for osteoarthritis, a condition affecting 32 million Americans, following a $100 million-plus investment over three years announced in 2023. • Research teams are contractually required to begin patient testing within 18 months, marking a shift from traditional federal research timelines. • This initiative addresses the painful joint degeneration disease, with solutions now progressing toward clinical trials amid high prevalence in the US population.